Good morning :)
Place Order
Add to Watchlist

Epigral Ltd

EPIGRAL

Epigral Ltd

EPIGRAL
MaterialsCommodity Chemicals
SmallcapWith a market cap of ₹8,029 cr, stock is ranked 570
High RiskStock is 3.99x as volatile as Nifty
1,750.605.94% (-110.50)
1,750.605.94% (-110.50)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
MaterialsCommodity Chemicals
SmallcapWith a market cap of ₹8,029 cr, stock is ranked 570
High RiskStock is 3.99x as volatile as Nifty

How to use scorecard? Learn more

MaterialsCommodity Chemicals
SmallcapWith a market cap of ₹8,029 cr, stock is ranked 570
High RiskStock is 3.99x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
23.076.130.26%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
27.823.161.50%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Epigral Limited (formerly Meghmani Finechem Limited) is a manufacturer of essential chemicals, primarily focused on the production of chlor alkali and its derivatives, used across various industries.

Investor Presentation

View older 

Jan 27, 2025

PDF
View Older Presentations
PE Ratio
95.34
1Y Return
26.24%
Buy Reco %
80.00
LINDEINDIA
PE Ratio
111.85
1Y Return
0.51%
Buy Reco %
50.00
PE Ratio
37.65
1Y Return
15.79%
Buy Reco %
42.86
PE Ratio
65.33
1Y Return
25.40%
Buy Reco %
100.00
PE Ratio
52.78
1Y Return
16.55%
Buy Reco %
100.00
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2021FY 2022FY 2023FY 2024TTM
Total Revenue830.791,555.052,196.381,935.782,461.93
Raw Materialssubtract386.52759.411,211.761,071.601,754.54
Power & Fuel Costsubtract27.9364.15145.56141.32
Employee Costsubtract41.2651.9968.8581.31
Selling & Administrative Expensessubtract21.3547.8557.0154.12
Operating & Other expensessubtract90.22118.0616.3099.64
Depreciation/Amortizationsubtract73.5485.91108.95123.56128.99
Interest & Other Itemssubtract29.1144.2765.5073.4955.19
Taxes & Other Itemssubtract60.02130.63169.1794.88175.14
EPS24.2760.8485.0247.1483.77
DPS0.000.005.005.005.00
Payout ratio0.000.000.060.110.06

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Jun 7PDF
FY 2023

Annual report

PDF

Investor Presentation

Apr 25PDF
Jan 24PDF
Jan 19PDF
+3 more
FY 2024

Annual report

PDF

Investor Presentation

Aug 16PDF
Aug 5PDF
FY 2025

Annual Report Pending

Investor Presentation

Jan 27PDF
 

Peers & Comparison

Comparing 3 stocks from 
MaterialsCommodity Chemicals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Epigral Ltd40.996.130.26%
Solar Industries India Ltd95.3423.250.10%
Linde India Ltd111.8514.000.21%
Deepak Nitrite Ltd37.656.330.34%

Price Comparison

Compare EPIGRAL with any stock or ETF
Compare EPIGRAL with any stock or ETF
EPIGRAL
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 2.65%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding68.94%4.15%0.16%3.01%23.75%

Jun 2024

Sep 2024

Oct 2024

Dec 2024

Shareholding History

Dec '23MarJunSepOctDec '241.18%1.36%1.47%2.09%3.02%3.01%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 3.12%

Top 5 Mutual Funds holding Epigral Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.4709%0.89%-0.05%50/105 (+22)
0.2990%0.20%0.01%87/103 (-6)
0.2197%1.09%-0.08%26/110 (-6)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateFeb 7, 2025

Interim
Interim | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Feb 7, 2025

Cash Dividend

Ex DateEx DateJul 2, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Jul 2, 2024

Cash Dividend

Ex DateEx DateJun 20, 2023

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Jun 20, 2023

Cash Dividend

Ex DateEx DateFeb 1, 2023

Interim
Interim | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Feb 1, 2023

News & Opinions
Earnings
Epigral consolidated net profit rises 111.15% in the December 2024 quarter

Net profit of Epigral rose 111.15% to Rs 103.63 crore in the quarter ended December 2024 as against Rs 49.08 crore during the previous quarter ended December 2023. Sales rose 36.84% to Rs 645.24 crore in the quarter ended December 2024 as against Rs 471.52 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales645.24471.52 37 OPM %28.2925.99 - PBDT186.53104.81 78 PBT153.6273.93 108 NP103.6349.08 111 Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Epigral fixes record date for interim dividend

Epigral has fixed 7 February 2025 as record date for payment of interim dividend for FY 2024-25. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Board of Epigral recommends Interim Dividend

Epigral announced that the Board of Directors of the Company at its meeting held on 27 January 2024, has recommended a Interim dividend of Rs.2.5 per share (i.e.25%), subject to the approval of the shareholders.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Epigral declare Quarterly Result

Epigral will hold a meeting of the Board of Directors of the Company on 27 January 2025.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Epigral consolidated net profit rises 114.00% in the September 2024 quarter

Net profit of Epigral rose 114.00% to Rs 81.30 crore in the quarter ended September 2024 as against Rs 37.99 crore during the previous quarter ended September 2023. Sales rose 30.93% to Rs 626.06 crore in the quarter ended September 2024 as against Rs 478.15 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales626.06478.15 31 OPM %28.5022.53 - PBDT157.4387.45 80 PBT125.1855.94 124 NP81.3037.99 114 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Board of Epigral approves doubling of capacity at Dahej

The Board of Epigral at its meeting held on 09 November 2024 has approved the expansion of production capacity of Chlorinated Polyvinyl Chloride Resin (CPVC Resin) and Epichlorohydrin at Dahej, Gujarat at an estimated capex of Rs 780 crore. Details: CPVC Resin - Proposed capacity addition 75,000 TPA (existing capacity 75,000 TPA; 65% capacity utilization) Epichlorohydrin - Proposed capacity addition 50,000 TPA (existing capacity 50,000 TPA; 80% capacity utilization) Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Epigral to table results

Epigral will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Epigral allots 15.19 lakh equity shares under QIP issue

Epigral has allotted 15,19,180 equity shares at an issue price of Rs 2093.13 per equity share under QIP issue for a consideration of Rs 333.05 crore. With this allotment, the paid up equity share capital has increased to Rs 43,14,13,380 consisting of 4,31,41,338 equity shares. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Board of Epigral approves fund raising up to Rs 500 cr

The Board of Epigral at its meeting held on 14 August 2024 has approved fund raising up to Rs 500 crore through issue of securities on preferential allotment basis or qualified institutional placement. Powered by Capital Market - Live

6 months agoCapital Market - Live
Corporate
Epigral to convene board meeting

Epigral will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

6 months agoCapital Market - Live